AIxCrypto Holdings, Inc.

NasdaqCM:AIXC Stock Report

Market Cap: US$29.1m

AIxCrypto Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for AIxCrypto Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth24.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Dec 30

Is AIxCrypto Holdings (NASDAQ:AIXC) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 16

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Qualigen Therapeutics press release (NASDAQ:QLGN): Q2 GAAP EPS of -$0.11 beats by $0.06. Revenue of $1.4M (+25.0% Y/Y) beats by $0.05M. As of June 30, 2022, Qualigen Therapeutics had $9.7 million in cash. The Company believes its cash is sufficient to fund its anticipated operations into 2023.
Seeking Alpha • Jul 29

Qualigen Therapeutics files mixed shelf offering of up to $150M

Qualigen Therapeutics (NASDAQ:QLGN) on Friday filed for a mixed shelf offering of up to $150M. The company disclosed the offering in a S-3 filing with the U.S. SEC after hours. The offering consists of a combination of common stock, preferred stock, debt securities, warrants, rights and units. Carlsbad, Calif.-based Qualigen (QLGN) develops cancer therapies. QLGN stock was down 2.1% to $0.41 in postmarket trading. It earlier closed -2.8% at $0.42.
Seeking Alpha • Jul 06

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Qualigen Therapeutics (NASDAQ:QLGN) on Wednesday said it would partner China-based Hande Sciences to scale-up manufacturing to support investigational new drug application enabling studies for its QN-302 inhibitor platform. QLGN is developing QN-302 as a potential treatment for a type of pancreatic cancer called pancreatic ductal adenocarcinoma, in addition to other cancers such as prostate. The agreement with Hande provides for process development and scale-up batches of material for QLGN’s toxicology studies on QN-302, which QLGN expects to commence in Q3 2022. QLGN said it is on track to complete its investigational new drug application studies for QN-302 in Q3 and Q4 2022. QLGN stock -0.7% at $0.50 in morning trading.
Analysis Article • Mar 08

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Nov 23

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AIxCrypto Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:AIXC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-20-7-7N/A
9/30/2025N/A-8-7-7N/A
6/30/2025N/A-7-7-7N/A
3/31/2025N/A-7-7-7N/A
12/31/2024N/A-6-6-6N/A
9/30/2024N/A-8-10-10N/A
6/30/2024N/A-9-7-7N/A
3/31/2024N/A-11-8-8N/A
12/31/2023N/A-12-10-10N/A
9/30/2023N/A-14-7-7N/A
6/30/2023-2-12-11-11N/A
3/31/2023-1-13-12-12N/A
12/31/2022N/A-14-13-13N/A
9/30/20221-15-14-14N/A
6/30/20225-16-14-14N/A
3/31/20224-17-17-17N/A
12/31/20216-18-15-15N/A
9/30/20215-7-15-15N/A
6/30/20215-12-17-17N/A
3/31/20215-25-13-12N/A
12/31/20204-20-10-10N/A
9/30/20205-28-8-7N/A
6/30/20205-20-2-2N/A
3/31/20206-200N/A
12/31/20195-1-1-1N/A
3/31/20196-1N/A-1N/A
3/31/2018100N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AIXC's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if AIXC's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if AIXC's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if AIXC's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AIXC's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AIXC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 03:07
End of Day Share Price 2026/05/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AIxCrypto Holdings, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
David BautzZacks Small-Cap Research